JP2024513538A - Ｐａｒｐ阻害剤としての置換融合二環式化合物及びその使用 - Google Patents

Ｐａｒｐ阻害剤としての置換融合二環式化合物及びその使用 Download PDF

Info

Publication number
JP2024513538A
JP2024513538A JP2024505487A JP2024505487A JP2024513538A JP 2024513538 A JP2024513538 A JP 2024513538A JP 2024505487 A JP2024505487 A JP 2024505487A JP 2024505487 A JP2024505487 A JP 2024505487A JP 2024513538 A JP2024513538 A JP 2024513538A
Authority
JP
Japan
Prior art keywords
methyl
ethyl
piperazin
tetrahydroquinazolin
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513538A5 (https=
Inventor
スイ ション ツァイ，
イェ エドワード ティアン，
シャオジュー ワン，
Original Assignee
インパクト セラピューティクス （シャンハイ）， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インパクト セラピューティクス （シャンハイ）， インコーポレイテッド filed Critical インパクト セラピューティクス （シャンハイ）， インコーポレイテッド
Publication of JP2024513538A publication Critical patent/JP2024513538A/ja
Publication of JP2024513538A5 publication Critical patent/JP2024513538A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024505487A 2021-04-12 2022-04-12 Ｐａｒｐ阻害剤としての置換融合二環式化合物及びその使用 Pending JP2024513538A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110392892 2021-04-12
CN202110392892.4 2021-04-12
CN202110707739.6 2021-06-24
CN202110707739 2021-06-24
CN202111065912 2021-09-10
CN202111065912.3 2021-09-10
PCT/CN2022/086311 WO2022218296A1 (en) 2021-04-12 2022-04-12 Substituted fused bicyclic compounds as parp inhibitors and the use thereof

Publications (2)

Publication Number Publication Date
JP2024513538A true JP2024513538A (ja) 2024-03-25
JP2024513538A5 JP2024513538A5 (https=) 2025-05-08

Family

ID=83640149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505487A Pending JP2024513538A (ja) 2021-04-12 2022-04-12 Ｐａｒｐ阻害剤としての置換融合二環式化合物及びその使用

Country Status (8)

Country Link
US (1) US20240208969A1 (https=)
EP (1) EP4326713A4 (https=)
JP (1) JP2024513538A (https=)
KR (1) KR20240009929A (https=)
CN (3) CN117653636B (https=)
CA (1) CA3216489A1 (https=)
MX (1) MX2023012039A (https=)
WO (1) WO2022218296A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024050370A1 (en) * 2022-08-30 2024-03-07 1Cbio, Inc. Heterocyclic compounds and methods of use thereof
KR20250103668A (ko) * 2022-11-10 2025-07-07 치아타이 티안큉 파마수티컬 그룹 주식회사 축합 이환 화합물
TW202506680A (zh) * 2023-04-28 2025-02-16 美商思諾維新醫藥公司 作為ｐａｒｐ１抑制劑之雜環化合物

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018781A2 (en) * 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
JP2007515431A (ja) * 2003-12-19 2007-06-14 イーライ リリー アンド カンパニー 三環系のステロイドホルモン核内受容体モジュレータ
JP2008530212A (ja) * 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有するピペラジン−ピペリジン
JP2011500758A (ja) * 2007-10-26 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
JP2011515451A (ja) * 2008-03-27 2011-05-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チューブリン重合阻害剤としてのキナゾリノン誘導体
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd ２−アミノ置換８−オキソジヒドロプリン誘導体
JP2014509615A (ja) * 2011-04-01 2014-04-21 南京インパクト薬業有限会社 Ｐａｒｐ抑制剤としての１−（アリ−ルメチル）キナゾリン−２，４（１ｈ，３ｈ）−ジオン及びその用途
JP2017508756A (ja) * 2014-03-07 2017-03-30 中国科学院上海薬物研究所Ｓｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ 複素環式化合物、その製造方法および使用
JP2017510564A (ja) * 2014-02-27 2017-04-13 ミュタビリスＭｕｔａｂｉｌｉｓ 新規なヘテロ芳香族誘導体およびそれらの医薬としての使用
WO2018112842A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
JP2019528298A (ja) * 2016-08-22 2019-10-10 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｐｄｅ４阻害剤
JP2019529364A (ja) * 2016-08-22 2019-10-17 メッドシャイン ディスカバリー インコーポレイテッド Ｐｄｅ４阻害剤としての縮合環系化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001302515A (ja) * 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
JP2002284699A (ja) * 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
EA011552B1 (ru) * 2004-06-30 2009-04-28 Янссен Фармацевтика Н.В. Производные хиназолиндиона в качестве ингибиторов parp
JP2007137818A (ja) * 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd ８−ヒドロキシ−２，４（１ｈ，３ｈ）−キナゾリンジオン誘導体
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5744019B2 (ja) * 2009-07-14 2015-07-01 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 選択的ｐａｒｐ−１阻害を有する３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−カルボキサミド
CA2829123C (en) * 2011-03-14 2016-04-12 Eternity Bioscience Inc. Quinazolinediones and their use
CN102731416A (zh) * 2011-04-01 2012-10-17 南京英派药业有限公司 1-(芳基甲基)-喹唑啉-2，4-二酮作为parp抑制剂及其应用
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
SI3999506T1 (sl) * 2019-07-19 2025-06-30 Astrazeneca Ab Zaviralci PARP1

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018781A2 (en) * 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
JP2007515431A (ja) * 2003-12-19 2007-06-14 イーライ リリー アンド カンパニー 三環系のステロイドホルモン核内受容体モジュレータ
JP2008530212A (ja) * 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有するピペラジン−ピペリジン
JP2011500758A (ja) * 2007-10-26 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
JP2011515451A (ja) * 2008-03-27 2011-05-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チューブリン重合阻害剤としてのキナゾリノン誘導体
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd ２−アミノ置換８−オキソジヒドロプリン誘導体
JP2014509615A (ja) * 2011-04-01 2014-04-21 南京インパクト薬業有限会社 Ｐａｒｐ抑制剤としての１−（アリ−ルメチル）キナゾリン−２，４（１ｈ，３ｈ）−ジオン及びその用途
JP2017510564A (ja) * 2014-02-27 2017-04-13 ミュタビリスＭｕｔａｂｉｌｉｓ 新規なヘテロ芳香族誘導体およびそれらの医薬としての使用
JP2017508756A (ja) * 2014-03-07 2017-03-30 中国科学院上海薬物研究所Ｓｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ 複素環式化合物、その製造方法および使用
JP2019528298A (ja) * 2016-08-22 2019-10-10 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｐｄｅ４阻害剤
JP2019529364A (ja) * 2016-08-22 2019-10-17 メッドシャイン ディスカバリー インコーポレイテッド Ｐｄｅ４阻害剤としての縮合環系化合物
WO2018112842A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"RN:1326818-33-0等、全５０化合物", DATABASE REGISTRY, JPN7026001174, 16 April 2019 (2019-04-16), ISSN: 0005821316 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. Vol.18(19), JPN6026011252, 2008, pages 5285 - 5289, ISSN: 0005821315 *
JOURNAL OF ORGANIC CHEMISTRY, vol. Vol.81(11), JPN6026011253, 2016, pages 4898 - 4905, ISSN: 0005821317 *

Also Published As

Publication number Publication date
CN116783181B (zh) 2026-01-30
CN117653636A (zh) 2024-03-08
EP4326713A4 (en) 2025-03-19
WO2022218296A1 (en) 2022-10-20
EP4326713A1 (en) 2024-02-28
KR20240009929A (ko) 2024-01-23
CA3216489A1 (en) 2022-10-20
CN116783181A (zh) 2023-09-19
MX2023012039A (es) 2024-03-05
CN121800782A (zh) 2026-04-07
US20240208969A1 (en) 2024-06-27
CN117653636B (zh) 2024-04-26

Similar Documents

Publication Publication Date Title
JP2024531477A (ja) Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用
JP7240784B2 (ja) ８，９－ジヒドロイミダゾール［１，２－ａ］ピリミド［５，４－ｅ］ピリミジン－５（６Ｈ）－ケトン類化合物
WO2022199652A1 (en) Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
CN112142744A (zh) 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
JP2025508122A (ja) Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用
WO2017092635A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
JP2024513538A (ja) Ｐａｒｐ阻害剤としての置換融合二環式化合物及びその使用
JP2024540921A (ja) Ｕｓｐ１阻害剤としての置換トリアゾロヘテロアリール化合物及びその応用
JP2022547294A (ja) キナーゼ阻害剤としての３，５－ジ置換ピラゾール化合物およびその応用
CN116670134A (zh) 取代的咪唑并[1,5-b]哒嗪化合物作为激酶抑制剂及其应用
WO2024083237A1 (en) Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof
WO2024179547A1 (en) Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
JP2022548055A (ja) 置換イミダゾキノキサリン化合物およびその応用
HK40115331A (zh) 作为parp抑制剂的取代的三环类化合物及其应用

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250414

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260323